Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval

Jazz Pharmaceuticals’ $1 billion bet last year looks to be paying off so far: for them and their partner.

Seven months after the Irish biopharma licensed PharmaMar’s small cell lung cancer drug lurbinectedin, the FDA has granted it accelerated approval. The drug, which was submitted two days before Jazz signed on in December and later granted priority review, will be marketed as Zepzelca.